FDA approved the first-ever long-acting injectable drug for HIV prevention


The U.S. Food and Drug Administration has approved the first-ever long-acting injectable , as a response to the global efforts in this matter. “This injection, given every two months, will be critical to addressing the HIV epidemic in the U.S., including helping high-risk individuals and certain groups where adherence to daily medication has been a major challenge or not a realistic option,” the FDA said in a statement. Experts say “this is a game-changer in the world of HIV prevention.” CDC data shows that an estimated 34,800 people in the United States acquired HIV in 2019. Heterosexual people made up 23% of all HIV diagnoses in the U.S. There were approximately 37.7 million people across the globe with HIV in 2020. Of these, 36 million were adults and 1.7 million were children aged 0-14 years. „More discreet HIV prevention option that may be more desirable for some people,” the National Institute of Allergy and Infectious Diseases appreciated.


At this time, ther is not an efficient cure for HIV infection. HIV became instead a manageable chronic health condition. In 2020, 680,000 people died from HIV-related causes. The human immunodeficiency virus (HIV) targets the immune system and weakens people’s defense against many infections and some types of cancer. The Sixty-Ninth World Health Assembly endorsed the “Global health sector strategy on HIV for 2016 – 2021” which includes as strategic direction the innovation for acceleration in prevention.